|
Market Closed -
Nasdaq
00:00:00 12/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 53.87 USD | -2.34% |
|
-5.16% | +11.12% |
| 07-13 | GSK posts encouraging data for bowel cancer treatment Jemperli | AN |
| 06-29 | AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from Russell 3000E Growth Benchmark | CI |
| Market Cap | 1.6B 1.37B 1.3B 1.18B 2.21B 152B 2.22B 15.45B 5.94B 77.52B 5.99B 5.86B 245B | P/E 2026 * |
1,628x | P/E 2027 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise Value | 1.5B 1.29B 1.23B 1.11B 2.08B 144B 2.1B 14.56B 5.6B 73.04B 5.64B 5.52B 231B | EV / Sales 2026 * |
14.2x | EV / Sales 2027 * | 7.56x |
| Free-Float |
94.32% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ANAB | Delayed | |
CBOE
| ANAB | Real-time | |
|
Deutsche Boerse AG
| AN6 | Delayed | |
|
Tradegate
| AN6 | Real-time | |
|
Börse Stuttgart
| AN6 | Delayed | |
|
Boerse Muenchen
| AN6 | Real-time |
Last Transcript : AnaptysBio, Inc.
| 1 day | -2.34% | ||
| 1 week | -5.16% | ||
| Current month | -5.54% | ||
| 1 month | -3.84% | ||
| 3 months | -3.92% | ||
| 6 months | -16.88% | ||
| Current year | +11.12% |
| 1 week | 53.75 |  | 58.16 |
| 1 month | 53.75 | | 60.31 |
| Current year | 42 | | 73.3 |
| 1 year | 17.11 | | 73.3 |
| 3 years | 12.21 | | 73.3 |
| 5 years | 12.21 | | 73.3 |
| 10 years | 10 | | 134 |
| Manager | Title | Age | Since |
|---|---|---|---|
Daniel Faga
CEO | Chief Executive Officer | 46 | 21/03/2022 |
| Director of Finance/CFO | 42 | 11/05/2026 | |
Benjamin Stone
PRN | Corporate Officer/Principal | 35 | 01/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Hollings Renton
BRD | Director/Board Member | 79 | 30/06/2015 |
John Schmid
BRD | Director/Board Member | 63 | 30/06/2015 |
Oleg Nodelman
BRD | Director/Board Member | 49 | 08/04/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 11/05/26 | Free | Director | 11,250 | 0.0391% | ||
| 11/05/26 | Free | Chief Financial Officer | 25,765 | 0.0896% | ||
| 27/04/26 | Free | Director | 11,250 | 0.0391% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.34% | -5.16% | +130.21% | +175.97% | 1.6B | |
| -2.11% | -1.68% | +43.40% | +95.58% | 66.93B | |
| -0.23% | -4.45% | +32.50% | +77.58% | 61.97B | |
| +1.67% | +2.47% | -11.32% | +392.05% | 28.26B | |
| -1.05% | -4.43% | +28.84% | +12.17% | 24.59B | |
| +0.34% | -6.78% | -0.01% | -14.59% | 24.3B | |
| +0.43% | -3.37% | +16.22% | -17.48% | 19.41B | |
| -3.03% | -2.29% | +181.72% | +333.47% | 16.77B | |
| -1.94% | -4.94% | -8.15% | +519.85% | 14.18B | |
| +3.24% | -0.31% | -7.34% | +833.51% | 14B | |
| Average | -0.50% | -3.17% | +40.61% | +240.81% | 27.2B | |
| Weighted average by Cap. | -0.57% | -2.84% | +31.84% | +172.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 106M 91.09M 86.25M 78.18M 147M 10.1B 147M 1.02B 394M 5.14B 397M 388M 16.24B | 172M 148M 140M 127M 239M 16.45B 240M 1.67B 642M 8.37B 647M 632M 26.44B |
| Net income | 619K 533K 505K 458K 859K 59.15M 863K 6M 2.31M 30.09M 2.33M 2.27M 95.08M | 148M 128M 121M 110M 206M 14.17B 207M 1.44B 553M 7.21B 557M 545M 22.78B |
| Net Debt | -92.22M -79.46M -75.24M -68.2M -128M -8.81B -129M -894M -344M -4.48B -346M -339M -14.16B | -293M -252M -239M -217M -407M -28B -409M -2.84B -1.09B -14.24B -1.1B -1.08B -45.01B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/09/26 | $53.87 | -2.34% | 336,187 |
| 10/09/26 | $55.16 | -0.97% | 300,154 |
| 09/09/26 | $55.70 | -1.59% | 295,684 |
| 08/09/26 | $56.60 | -0.35% | 1,036,084 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ANAB Stock
Select your edition
All financial news and data tailored to specific country editions
